
Results: 212 patients included: 53 with BL allergy and 159 without BL allergy. There were no significant differences in baseline or infection characteristics. Among BL allergic patients: 26 (49%) had an immune mediated reaction, 8 (15%) had a reaction that was intolerance and not allergy, and 19 (36%) had an unspecified reaction. Of 53 allergic patients, desensitization occurred in one patient; allergy consults were completed for 13% of patients. Optimal antibiotics were given to 135 patients without a BL allergy and 37 patients with a BL allergy (85% vs. 70%, P=0.015). Nafcillin or cefazolin was the optimal antibiotic used in 95% of patients. Median time to optimal antibiotics was 29 hours for both groups (P=0.64). No differences were found in clinical cure (79% vs 81%, P=0.76) or mortality (19% vs 18%, P=0.84). Infectious disease consults were more common among BL allergic (89% vs 75%, P=0.04), and were associated with an increased usage of optimal antibiotics (68% vs 13%, P<0.001), as seen in Table 1.
Conclusion: Patients with a documented BL allergy were less likely to receive optimal antibiotics for MSSA BSI. Patient outcomes may be improved with routine use of infectious disease consult to optimize therapy in patients who report BL allergies.
Table 1. Characteristics associated with optimal antibiotics |
n, % Total population |
Unadjusted OR 95% CI |
Adjusted OR 95% CI |
Beta-lactam allergy |
53 (25) |
0.41 (0.2-0.85) |
0.3 (0.1-0.6) |
ID consult |
167 (79) |
4.4 (2.1-9.3) |
6.1 (2.7-13.9) |
Immunosuppressed |
25 (12) |
2.9 (0.66-1.3) |
2.9 (0.6-13.8) |

S. January,
None
M. Veve, None
E. Zoratti, None
M. Zervos, Pfizer: Research Contractor , Research support
Cerexa: Research Contractor , Research support
Cubist: Research Contractor , Research support
Merck: Research Contractor , Research support
Tetraphase: Research Contractor , Research support
Melinta: Research Contractor , Research support
Paratek: Research Contractor , Research support
Rempex: Research Contractor , Research support
Cempra: Grant Investigator , Research support
S. L. Davis, None